Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)

• Status: Completed
• Trial end date: 2017-01-24
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to examine inhalation behavior in patients enrolled in the German Ventavis patient support program Ventaplus when these patients are switched from Ventavis (Iloprost) 10 μg/mL to Ventavis (Iloprost) 20 μg/mL formulation.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Iloprost

Criteria

Inclusion Criteria:

• Patients aged ≥18 years at time of signing informed consent.

• Patients, diagnosed with group 1 PAH.

• Patients must be enrolled in the German Ventavis patient support program Ventaplus.

• Patients who either already switched from V10 to V20 therapy or who agreed to do so according to their physician's decision.

• Patients must have been on V10 therapy for at least 2 weeks.

• Written informed consent must be obtained.

Exclusion Criteria:

• participation in other clinical or interventional study.